Stocks Health care AMRX
NASDAQ · Health careAmneal Pharmaceuticals, Inc. (AMRX)
Amneal Pharmaceuticals, Inc. brought in $3.1B of revenue over the twelve months to June 30, 2026, up 9.3% from a year earlier. Net income was $157.4M, a net margin of 5.0%. Operating cash flow minus capital spending left $269.9M of free cash flow in fiscal 2025. At June 30, 2026 it held $127.6M in cash against $2.6B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Amneal Pharmaceuticals, Inc. does
Amneal Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AMRX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $3B | $72.1M | $0.22 | $269.9M |
| 2024 | $2.8B | -$116.9M | -$0.38 | $243.2M |
| 2023 | $2.4B | -$84M | -$0.48 | $302.4M |
| 2022 | $2.2B | -$270.6M | -$0.86 | $18.7M |
| 2021 | $2.1B | $13.2M | $0.07 | $194.1M |
| 2020 | $2B | $67.8M | $0.61 | $322.6M |
Latest SEC filings
What Amneal Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 3, 2026
- August 12, 2026Activist stake changed SCHEDULE 13D/A
- August 12, 2026Activist stake changed SCHEDULE 13D/A
- August 12, 2026Activist stake changed SCHEDULE 13D/A
- August 10, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- August 3, 2026
- July 31, 2026
- July 30, 2026Additional proxy material DEFA14A
- July 30, 2026
Questions about AMRX
What does Amneal Pharmaceuticals, Inc. do?
Amneal Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AMRX.
Is Amneal Pharmaceuticals, Inc. profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $157.4M on revenue of $3.1B, a net margin of 5.0%.
How much revenue does Amneal Pharmaceuticals, Inc. make?
Over the twelve months to June 30, 2026 Amneal Pharmaceuticals, Inc. reported revenue of $3.1B. That is 9.3% more than a year earlier.
When did Amneal Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 21, 2026.
Similar companies
Follow AMRX
Get an email when Amneal Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow AMRX: get an email when it filesWhere the numbers come from
Financial figures are the values Amneal Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.